fda update

On March 6, 2018, the U.S. Food and Drug Administration (FDA) approved updated dosing information for nivolumab (Opdivo®). Nivolumab is now the first FDA-approved PD-1 inhibitor that offers a flexible dosing option of every two weeks at 240 mg or every four weeks at 480 mg for most approved indications. The manufacturer, Bristol-Meyers Squibb, maintains a list of approved indications. Nivolumab has also been approved for 30-minute infusions across all indications, reducing previous administration times by 50%.

Nivolumab has been approved for a number of indications to treat cancers, including hepatocellular carcinoma, colorectal cancers, advanced or metastatic bladder cancer, and more. Stay up to date on emerging FDA approvals through ONS Voice.

Add new comment

About text formats

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.